Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 10.08.2026 2 Am J Gastroenterol 1 Biochem Biophys Res Commun 3 BMC Cancer 4 BMC Gastroenterol 5 Dig Dis Sci 1 Endoscopy 1 Eur Radiol 3 Gut 3 Hepatology 1 Int J Cancer 6 J Gastroenterol Hepatol 2 J Hepatol 2 Oncogene 3 PLoS One 1 Proc Natl Acad Sci U S A 3 Radiology 2 Semin Liver Dis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. SILVEY S, Patel N, O'Leary JG, Bajaj JS, et al
   Validation of Liver Cirrhosis Network Criteria for Compensated Cirrhosis Through Natural Language Processing for Predicting Liver-Related Events.
   Am J Gastroenterol. 2026 Aug 4. doi: 10.14309/ajg.0000000000004179.
   PubMed         Abstract available
   
   
2. WANG J, Yang L, Gong Z, Zhao M, et al
   Metabolically healthy obesity, its resolution, and the risk of incident hepatic steatosis in Chinese children: evidence from two prospective cohorts.
   Am J Gastroenterol. 2026 Aug 3. doi: 10.14309/ajg.0000000000004173.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

3. WANG M, Liu H, Guo C, Li H, et al
   SERBP1 promoter single nucleotide polymorphism (SNP) rs3762314: a genetic susceptibility biomarker promoting malignant phenotype in hepatocellular carcinoma.
   Biochem Biophys Res Commun. 2026;832:154370.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. XU XQ, Li WM, Shi LC, Wang H, et al
   Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy.
   BMC Cancer. 2026;26:937.
   PubMed         Abstract available
   
   
5. ZHAO S, Li H, Wang Q, Su C, et al
   Retraction Note: The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated alpha(2)M.
   BMC Cancer. 2026;26:945.
   PubMed        
   
   
6. ZHANG Y, Zhang T, Yin Q, Luo H, et al
   Retraction Note: Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma.
   BMC Cancer. 2026;26:935.
   PubMed        
   
   

   
   BMC Gastroenterol

7. SHI X, Zhu S, Sang N, Jin L, et al
   Post-splenectomy early biochemical trajectories and predictors in 935 patients with Wilson disease: a group-based trajectory modeling study.
   BMC Gastroenterol. 2026;26:493.
   PubMed         Abstract available
   
   
8. YUAN Y, Tan Q, Zhu M, Chen L, et al
   ETV4 as a potential target gene for alleviating proliferation metastasis of HCC.
   BMC Gastroenterol. 2026;26:491.
   PubMed         Abstract available
   
   
9. ALASHQAR M, Abu Kamesh MI, Alsadi R, Khader M, et al
   An unusual superior mesenteric arteriovenous malformation causing obscure gastrointestinal bleeding: a case report.
   BMC Gastroenterol. 2026;26:487.
   PubMed         Abstract available
   
   
10. LUO YX, Niu WW, Zhang H, Shi XD, et al
    Endoscopic band ligation as a safe and effective minimally invasive treatment for large esophageal hemangioma: a case report.
    BMC Gastroenterol. 2026;26:484.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

11. KALAL CR, Poyekar S, Joshi H, Zanwar S, et al
    What a Placebo Arm Measures: Biopsy Misclassification and Embedded Lifestyle Care in Pooled Cirrhosis Incidence for Fibrotic MASH.
    Dig Dis Sci. 2026 Aug 8. doi: 10.1007/s10620-026-10155.
    PubMed        
    
    
12. LU Y, Zhu Z, Zhu Y, Zhu W, et al
    CASC15 Promotes Cholangiocyte Proliferation and Liver Fibrosis by Regulating the HNRNPU-IGFBP3 Axis in Biliary Atresia.
    Dig Dis Sci. 2026 Feb 13. doi: 10.1007/s10620-026-09748.
    PubMed         Abstract available
    
    
13. ZHANG K, Xu W, Kan C, Sheng S, et al
    Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990-2023.
    Dig Dis Sci. 2026;71:2976-2988.
    PubMed         Abstract available
    
    
14. PAPANTONIOU K, Driva TS, Sakellariou S, Machairas N, et al
    Perivascular Epithelioid Cell Tumor (PEComa): A Rare Type of Liver Cancer.
    Dig Dis Sci. 2026;71:2632-2635.
    PubMed         Abstract available
    
    
15. MERLI M, Di Cola S
    Not Just for Volume Anymore: New Indications for Albumin in Patients with Liver Disease.
    Dig Dis Sci. 2026;71:2664-2666.
    PubMed         Abstract available
    
    

    
    Endoscopy

16. KOGA T, Ishida Y, Matsumoto K, Fukuyama M, et al
    A long-scope technique for difficult intrahepatic bile duct puncture during endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026 Aug 4. doi: 10.1055/a-2919-0135.
    PubMed        
    
    

    
    Eur Radiol

17. BODALAL Z, Mendoza Ferradas FJ, Maxouri O, Iezzi R, et al
    Radiomics-based outcome prediction for irinotecan-TACE in colorectal liver metastases: advanced analysis from the prospective CIREL trial.
    Eur Radiol. 2026;36:6981-6996.
    PubMed         Abstract available
    
    

    
    Gut

18. WU K, Li L, Liu Y, Wang K, et al
    PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8(+) T cell dysfunction.
    Gut. 2026;75:1816-1830.
    PubMed         Abstract available
    
    
19. LUO PY, Ma M, Liu MC, Wu YH, et al
    Autophagy of Kupffer cells modulates CD8(+) T cell activation in primary biliary cholangitis.
    Gut. 2025 Dec 10:gutjnl-2025-335611. doi: 10.1136/gutjnl-2025-335611.
    PubMed         Abstract available
    
    
20. TOSHIKUNI N
    Can one dissemination time be assigned to polyclonal hepatocellular carcinoma recurrence?
    Gut. 2026 Aug 5:gutjnl-2026-340180. doi: 10.1136/gutjnl-2026-340180.
    PubMed        
    
    

    
    Hepatology

21. OHENE-MARFO P, Mohammed S, Jiang C, Bhaskaran S, et al
    Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD.
    Hepatology. 2026 Aug 4. doi: 10.1097/HEP.0000000000001830.
    PubMed         Abstract available
    
    
22. FIRDAUS Z, Khanal S, Washington AM, Solverson JK, et al
    With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1.
    Hepatology. 2026 Aug 6. doi: 10.1097/HEP.0000000000001833.
    PubMed         Abstract available
    
    
23. SINGAL AG, Agopian VG, Dawson LA, El-Khoueiry A, et al
    BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma.
    Hepatology. 2026 Aug 7. doi: 10.1097/HEP.0000000000001834.
    PubMed         Abstract available
    
    

    
    Int J Cancer

24. ROSE F, El-Ekiaby N, Wehling L, Weiler SME, et al
    A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.
    Int J Cancer. 2026;159:1829-1843.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

25. HE C, Wei Y, Zheng K, Wang X, et al
    Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2026 Jul 7. doi: 10.1111/jgh.70554.
    PubMed         Abstract available
    
    
26. LAU KC, Wong VW, Kong AP, Wong GL, et al
    Hepatic Steatosis and Low-Density Lipoprotein Cholesterol Response After Statin Initiation: A Prospective Cohort Analysis.
    J Gastroenterol Hepatol. 2026 Aug 7. doi: 10.1111/jgh.70656.
    PubMed         Abstract available
    
    
27. TADA T, Matono T, Kumada T
    Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".
    J Gastroenterol Hepatol. 2026 Aug 6. doi: 10.1111/jgh.70654.
    PubMed        
    
    
28. GILANI SAZ, Naseer M
    Post-ERCP Outcomes in Cirrhotics Patients With Thrombocytopenia: A Propensity-Matched Retrospective Comparative Analysis.
    J Gastroenterol Hepatol. 2026 Aug 6. doi: 10.1111/jgh.70638.
    PubMed        
    
    
29. JESWANI H, Jeswani AK
    Comment on Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
    J Gastroenterol Hepatol. 2026 Aug 4. doi: 10.1111/jgh.70655.
    PubMed        
    
    
30. WANG CW, Huang CF, Yeh ML, Liang PC, et al
    Association Between ADH1B rs1229984 Genetic Polymorphism and Hepatic Steatosis Assessed by CT Attenuation: A Mediation Analysis of Central Obesity in MASLD.
    J Gastroenterol Hepatol. 2026 Aug 4. doi: 10.1111/jgh.70632.
    PubMed         Abstract available
    
    

    
    J Hepatol

31. LI Y, Wang Y, Lu Y, Cai W, et al
    OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids.
    J Hepatol. 2026 Aug 4:S0168-8278(26)02753-4. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
32. ROMEO M, Dallio M, Napolitano C, Di Nardo F, et al
    Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis.
    J Hepatol. 2026 Aug 1:S0168-8278(26)02754-6. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    

    
    Oncogene

33. ZHANG H, Kong X, Qu H, Gao Y, et al
    Correction: MYCBP2-mediated HNF4alpha ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.
    Oncogene. 2026 Aug 3. doi: 10.1038/s41388-026-03948.
    PubMed        
    
    
34. SU T, Liao J, Dai Z, Xu L, et al
    Correction: Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.
    Oncogene. 2026 Aug 4. doi: 10.1038/s41388-026-03950.
    PubMed        
    
    

    
    PLoS One

35. WANG J, Wang H, Huang Z, Liu X, et al
    Disease burden and prediction of liver cancer attributable to metabolic risks in five East Asian countries from 1990 to 2023.
    PLoS One. 2026;21:e0342628.
    PubMed         Abstract available
    
    
36. ELSABAGH OA, Elgamal AM, Hassan HA, Ammar NM, et al
    Guazuma ulmifolia butanol extract protects against cadmium-induced hepatotoxicity via HO-1/Sirt-1 activation, miRNA-lncRNA modulation, and metabolic reprogramming.
    PLoS One. 2026;21:e0355464.
    PubMed         Abstract available
    
    
37. LIU S, Fu Y, Guo H, Li H, et al
    Optimization of extracellular vesicle extraction from hepatic tissue interstitial fluid and analysis of their ncRNA expression profiles.
    PLoS One. 2026;21:e0355303.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

38. LU Y, Gan L, Ru W, Guo Y, et al
    Co-phase separation of KRI1 and NPM1 sustains nucleolar integrity and ribosome biogenesis to fuel liver cancer progression.
    Proc Natl Acad Sci U S A. 2026;123:e2535921123.
    PubMed         Abstract available
    
    

    
    Radiology

39. WU X, Li J, Deng R, Xu X, et al
    Photon-counting CT Extracellular Volume Fraction for Liver Fibrosis Assessment: Validation against MR Elastography and Histopathology.
    Radiology. 2026;320:e253979.
    PubMed         Abstract available
    
    
40. YOO JS, Tak KY, Cho HS, Han JW, et al
    Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.
    Radiology. 2026;320:e253280.
    PubMed         Abstract available
    
    
41. DEYIRMENDJIAN C, Tang A
    Hepatic Arterial Infusion Chemotherapy as Second-line Therapy in Advanced Hepatocellular Carcinoma: An Early Career Perspective.
    Radiology. 2026;320:e262083.
    PubMed        
    
    

    
    Semin Liver Dis

42. GUPTA R, Florentino RM, Alenchery A, Berklite LE, et al
    Molecular Mechanisms of Progressive Familial Intrahepatic Cholestasis.
    Semin Liver Dis. 2026 Aug 7. doi: 10.1055/a-2933-3012.
    PubMed         Abstract available
    
    
43. KARABICICI M, Seki E
    Metabolic Dysfunction-Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche.
    Semin Liver Dis. 2026 Aug 4. doi: 10.1055/a-2921-0092.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum